Microorganisms and calcium oxalate stone disease

Nephron - Physiology

Volumn 98, Issue 2, 2004, Pages

  Goldfarb, David S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Nephrology Section/111G   (United States)

Author keywords

Calcium oxalate; Hyperoxaluria; Lactobacillus; Nanobacteria; Nephrolithiasis; Oxalates; Oxalobacter formigenes; Oxaluria; Urinary calculi; Urolithiasis

Indexed keywords

ANTIBIOTIC AGENT; APATITE; APATITE CARBONATE; CALCIUM OXALATE; OXALIC ACID; STRUVITE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; CALCIUM OXALATE STONE; DISEASE ASSOCIATION; HUMAN; HYPEROXALURIA; LACTIC ACID BACTERIUM; NONHUMAN; OXALOBACTER FORMIGENES; PATHOGENESIS; PRIORITY JOURNAL; PROTEUS; REVIEW; URINARY EXCRETION; URINARY TRACT INFECTION;

ANIMALS; CALCIUM OXALATE; CALCULI; HUMANS;

EID: 7544250436     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080264     Document Type: Review

References (36)

1. Abbott A: Battle lines drawn between 'nanobacteria' researchers. Nature 1999;401:105.
2. Kajander EO, Ciftcioglu N, Aho K, Garcia-Cuerpo E: Characteristics of nanobacteria and their possible role in stone formation. Urol Res 2003;31:47-54.
3. Sillitoe RH, Folk RL, Saric N: Bacteria as mediators of copper sulfide enrichment during weathering. Science 1996;272:1153-1155.
4. Kajander EO, Ciftcioglu N: Nanobacteria: An alternative mechanism for pathogenic intraand extracellular calcification and stone formation. Proc Natl Acad Sci USA 1998;95:8274-8279.
5. Maniloff J: Nannobacteria: Size limits and evidence. Science 1997;276:1776.
6. Kajander EO, Kuronen AP, Ciftçioglu N: Nanobacteria from blood, the smallest culturable autonomously replicating agent on Earth, in Instruments, methods, and missions for the investigation of extraterrestrial microorganisms. SPIE Proceedings Series, vol 3111. Washington, Society of Photo-Optical Instrumentation Engineers, 1997, pp 420-428.
7. Ciftcioglu N, Miller-Hjelle MA, Hjelle JT, Kajander EO: Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method. Antimicrob Agents Chemother 2002;46:2077-2086.
8. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M: Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003;111:607-616.
9. Akerman KK, Kuikka JT, Ciftcioglu N, Parkkinen J, Bergstrom KA, Kuronen I, Kajander EO: Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc SPIE Int Soc Opt Eng 1997;3111:436.
10. Ciftcioglu N, Bjorklund M, Kuorikoski K, Bergstrom K, Kajander EO: Nanobacteria: An infectious cause for kidney stone formation. Kidney Int 1999;56:1893-1898.
11. Garcia CE, Olavi KE, Ciftcioglu N, Lovaco CF, Correa C, Gonzalez J, Mampaso F, Liano F, Garcia DG, Escudero BA: Nanobacteria: An experimental neo-lithogenesis model. Arch Esp Urol 2000;53:291-303.
12. Cisar JO, Xu DQ, Thompson J, Swaim W, Hu L, Kopecko DJ: An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci USA 2000;97:11511-11515.
13. Allison MJ, Dawson KA, Mayberry WR, Foss JG: Oxalobacter formigenes gen. nov., sp. nov.: Oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 1985;141:1-7.
14. Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV: Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 1986;116:455-460.
15. Anantharam V, Allison MJ, Maloney PC: Oxalate: formate exchange: The basis for energy coupling in Oxalobacter. J Biol Chem 1989;264:7244-7250.
16. Sidhu H, Ogden SD, Lung HY, Luttge BG, Baetz AL, Peck AB: DNA sequencing and expression of the formyl coenzyme A transferase gene, frc, from Oxalobacter formigenes. J Bact 1997;179:3378-3381.
17. Sidhu H, Holmes RP, Allison MJ, Peck AB: Direct quantification of the enteric bacterium Oxalobacter formigenes in human fecal samples by quantitative competitive-template PCR. J Clin Microbiol 1999;37:1503-1509.
18. Hokama S, Honma Y, Toma C, Ogawa Y: Oxalate-degrading Enterococcus faecalis. Microbiol Immunol 2000;44:235-240.
19. Kwak C, Jeong BC, Kim HK, Kim EC, Chox MS, Kim HH: Molecular epidemiology of fecal Oxalobacter formigenes in healthy adults living in Seoul, Korea. J Endourol 2003;17:239-243.
20. Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD: Role of Oxalobacter formigenes in calcium oxalate stone disease: A study from north India. Eur Urol 2002;41:318-322.
21. Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, Peck AB: Absence of Oxalobacter formigenes in cystic fibrosis patients: A risk factor for hyperoxaluria. Lancet 1998;352:1026-1029.
22. Gibney EM, Goldfarb DS: The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis 2003;42:1-11.
23. Freel RW, Hatch M, Vaziri ND: Conductive pathways for chloride and oxalate in rabbit ileal brush-border membrane vesicles. Am J Physiol 1998;275:C748-C757.
24. Mittal RD, Kumar R, Mittal B, Prasad R, Bhandari M: Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract 2003;12:208-213.
25. Kwak C, Kim HK, Kim EC, Choi MS, Kim HH: Urinary oxalate levels and the enteric bacterium Oxalobacter formigenes in patients with calcium oxalate urolithiasis. Eur Urol 2003;44:475-481.
26. Troxel SA, Sidhu H, Kaul P, Low RK: Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol 2003;17:173-176.
27. Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB: Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999;10(suppl 14):S334-S340.
28. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A: Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.
29. Curhan GC: Dietary calcium, dietary protein, and kidney stone formation. Miner Electrolyte Metab 1997;23:261-264.
30. Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS: Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 2002;68:3841-3847.
31. Watterson JD, Cadieux PA, Beiko DT, Cook AJ, Burton JP, Harbottle RR, Lee C, Rowe E, Sidhu H, Reid G, Denstedt JD: Oxalate-degrading enzymes from Oxalobacter formigenes: A novel device coating to reduce urinary tract biomaterial-related encrustation. J Endourol 2003;17:269-274.
32. Graham DY, Yamaoka Y: Disease-specific Helicobacter pylori virulence factors: The unfulfilled promise. Helicobacter 2000;5(suppl 1): S3-9; discussion S27-31:S3-S9.
33. Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C: Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001;60:1097-1105.
34. Gionchetti P, Rizzello F, Venturi A, Campieri M: Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000;15:489-493.
35. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: A doubleblind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
36. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, Campieri M: Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 2002;97:1182-1186.